Patients undergoing BRAF/MEK inhibitor therapy for melanoma more commonly experience VKH-like uveitis compared with other malignancy types.

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

The new results from the BREAKWATER study – which is testing the combination of BRAF inhibitor Braftovi (encorafenib) with Eli Lilly's Erbitux (cetuximab) and chemotherapy – showed a ...

To fight this, doctors often use drugs called BRAF inhibitors, such as vemurafenib, which can stop the cancer’s growth—at ...

FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced two plixorafenib abstracts have been ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

or MEK inhibitors such as selumetinib (AZD6244). Since trials investigating the potential use of anti-BRAF agents in the management of gliomas are ongoing, it cannot be excluded, in case of ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

Reports cash, cash equivalents and marketable securities as of December 31 were $36.1M compared with $85.7M as of December 31, 2023. These ...